Thrombogenesis and anti-thrombogenesis in atherosclerosis mediated by prostanoids through the cyclooxygenase pathway

Current Topics in Atherosclerosis Research

Volumn , Issue , 2020, Pages 81-102

  Ruan, Ke He ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

And Thromboxane; Atherosclerosis; Cyclooxygenase; Prostaglandin; Prostanoid

Indexed keywords

EID: 85108925527     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Skultetyova, D., Filipova, S., Riecansky, I. and Mistrik, G. (2003) Endothelial dysfunction and the clinical application. Bratisl. Lek. Listy. 104, 40-41.
2. Linton, M.F., Fazio, S. (2002) Cyclooxygenase-2 and atherosclerosis. Curr. Opin. Lipidol. 13, 497-504.
3. Belton, O., Byrne, D., Kearney, D., Leahy, A. and Fitzgerald, D. (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 840-845.
4. Schonbeck, U., Sukhova, G.K., Graber, P., Coulter, S. and Libby, P. (1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281-1291.
5. Baker, C.S., Hall, R.J., Evans, T.J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M.H. and Polak, J.M. (1999) Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol. 19, 646-655.
6. Fitzgerald, G.A., Pedersen, A.K. and Patrono, C. (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67, 1174-1177.
7. Massy, Z.A. and Swan, S.K. (2001) Cyclooxygenase-2 and atherosclerosis: friend or foe? Nephrol. Dial Transplant. 16, 2286-2289.
8. Vane, J.R. (2002) Biomedicine. Back to an aspirin a day? Science 296, 474-475.
9. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J. and VIGOR Study Group. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520-1528.
10. Boers, M. (2001) NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet. 357, 1222-1223.
11. Golino, P., Crea, F. and Willerson, J.T. (2002) How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance. Ital. Heart J. 3, 220-225.
12. Majerus, P.W. (1983) Arachdonate metabolism in vascular disorders. J. Clin. Invest. 72, 1521-1525.
13. Miller, D.K., Sadowski, S., Soderman, D.D. and Kuehl, F.A.Jr. (1985) Endothelial cell prostacyclin production induced by activated neutrophils. J. Biol. Chem. 260, 1006-1014.
14. Smith, W.L. (1986) Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu. Rev. Physiol. 48, 251-262.
15. Needleman, P., Turk, J., Jackschik, B.A., Morrison, A.R. and Lefkowith, J.B. (1986) Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69-102.
16. Granstrom, E., Diczfalusy, U., Hamberg, M., Hansson, G., Malmsten, C. and Samuelson, B. (1982) Prostaglandins and the cardiovascular system (Oates, J.A., ed) pp. 15-58, Raven Press, New York.
17. Picot, D., Loll, P.J. and Garavitok, R.M. (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367, 243-249.
18. Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C. and Browner, M.F. (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 3, 927-933.
19. Ohashi, K., Ruan, K.-H., Kulmacz, R.J., Wu, K.K. and Wang, L.-H. (1992) Primary structure of human thromboxane synthase determined from the cDNA sequence. J. Biol. Chem. 267, 789-793.
20. Yokoyama, C., Miyata, A., Ihara, H., Ullrich, V. and Tanabe, T. (1991) Molecular cloning of human platelet thromboxane A synthase. Biochem. Biophys. Res. Commun. 178, 1479-1484.
21. Shen, R.-F., Back, S.J., Zhang, L., Chase, M.B., Tai, H.-H. and Purtell, D.C. (1982) Eighth Int. Conf. on prostaglandins and related compounds. Cloning, expression, and chromosomal mapping thromboxane synthase.
22. Haurand, M. and Ullrich, V. (1985) Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P450 enzyme. J. Biol. Chem. 260, 15059-15067.
23. Ullrich, V. and Graf, H. (1984) Prostacyclin and thromboxane synthase as P-450 enzymes. Trends Pharmacol. Sci. 5, 352-355.
24. Ravichandran, K. G., Boddupalli, S. S., Hasemann, C. A., Peterson, J. A., and Deisenhofer, J. (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450‘s. Science 261, 731-736.
25. Ruan, K.-H., Milfeld, K., Kulmacz, R.J. and Wu K.K. (1994) Comparison of the construction of a 3-D model for human thromboxane synthase using P450cam and BM-3 as templates: implications for the substrate binding pocket. Protein Eng. 7, 1345-1351.
26. Wang, L.-H., Matijevic-Aleksic, N., Hsu, P.Y., Ruan, K.-H., Wu, K.K. and Kulmacz, R.J. (1996) Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis. J. Biol. Chem. 33, 19970-19975.
27. Ushikubi, F., Nakajima, M., Hirata, M., Okuma, M., Fujiwara, M. and Narumiya, S. (1989) Purification of the thromboxane A2/prostagiandin H2, receptor from human blood platelets. J. Biol. Chem. 264, 16496-16501.
28. Hirata, M., Hayashi, Y., Ushikubi, F., Yokata, Y., Kageyama, R., Nakanishi, S., and Narumiya, S. (1991) Cloning and expression of cDNA for a human thromboxane A2, receptor. Nature 349, 617-620.
29. Katsuyama, M., Sugimoto, Y., Namba, T., Irie, A., Negishi, M., Narumiya, S. and Ichikawa, A. (1994) Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 344, 74-88.
30. Abrarnovitz, M., Boie, Y., Nguyen, T., Rushmore, T.H., Bayne, M.A., Metters, K.M., Slipetz, D.M. and Grygorczyk, R. (1994) Cloning and expression of a cDNA for tile human prostanoid FP receptor. J. Biol. Chem. 269, 1356-1360.
31. Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M. and Metters, K.M. (1993) Cloning and expression of CDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268, 26767-26772.
32. An, S., Yang, J., Xia, M. and Goetzl, E.J. (1993) Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun. 197, 263-270.
33. Bastien, L., Sawyer, N., Grygorczyk, R., Metters, M. and Adam, M. (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2, receptor. J. Biol. Chem. 269, 11873-11877.
34. Adam, M., Boie, Y., Rushmore, T.H., Muller, G., Bastien, L., McKee, K.T., Metters, K. M. and Abramovitz, M. (1994) Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett. 338, 170-174.
35. Regan, J.W., Bailey, T.J., Donello, J.E., Pierce, K.L., Pepperi, D.J., Zhang, D., Kedzie, K.M., Fairbaim, C.D., Bogardus, A.M., Woodward, D.F. and Gil, D.W. (1994) Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol. 112, 377-385.
36. Kunapuli, S.P., Mao, G.F., Bastepe, M., Liu-Chen, L.Y., Li, S., Cheung, P.P., DeRiel, J.K. and Ashby, B. (1994) Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukaemia cells. Biochem. J. 298, 263-267.
37. Yang, J., Xia, M., Goetzl, E. J. and An, S. (1994) Cloning and expression of the EP3- subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun. 198, 999-1006.
38. Kobayashi T, Narumiya S. (2002) Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 68-69, 557-573.
39. Narumiya, S. and FitzGerald, G.A. (2001) Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108, 25-30.
40. Sugimoto, Y., Narumiya, S. and Ichikawa A. (2000) Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 39, 289-314.
41. Thomas, D.W., Mannon, R.B., Mannon, P.J., Latour, A., Oliver, J.A., Hoffman, M., Smithies, O., Koller, B.H. and Coffman, T.M. (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest. 102, 1994-2001.
42. Negishi, M., Sugimoto, Y. and Ichikawa, A. (1995) Molecular mechanisms of diverse actions of prostanoid receptors. Biochim. Biophys. Acta 1259, 109-120.
43. Funk, C.D., Furci, L., Moran, N., and Fitzgerald, G.A. (1993) Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol. Pharmacol. 44, 934-939.
44. Yamamoto, Y., Kamiya, K. and Terao, S. (1993) Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. J. Med. Chem. 36, 820-825.
45. Chiang, N., Kan, W.M. and Tai, H.H. (1996) Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch. Biochem. Biophys. 334, 9-17.
46. Breyer, R.M and Audoly, L. (1997) The second extracellular loop of the prostaglandin EP3 receptor is an essential determinant of ligand selectivity. J. Biol. Chem. 272, 13475-13478.
47. Turek, J.W., Halmos, T., Sullivan, N.L., Antonakis, K. and Le Breton, G.C. (2002) Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J. Biol. Chem. 277, 16791-16797.
48. So, S.-P., Wu, J., Huang, G., Huang, A., Li, D. and Ruan, K.-H. (2003) Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J. Biol. Chem. 278, 10922-10927.
49. Henderson, R., Baldwin, J.M., Ceska, T.A., Zemlin, F., Beckmann, E. and Downing, K.H. (1990) Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol. 213, 899-929.
50. Grigorieff, N., Ceska, T.A., Downing, K.H., Baldwin, J.M. and Henderson, R. (1996) Electron-crystallographic refinement of the structure of bacteriorhodopsin. J. Mol. Biol. 259, 393-421.
51. Pebay-Peyroula, E., Rummell, G., Rosenbusch, J.P. and Landau, E.M. (1997) X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. Science 277, 1676-1681.
52. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M. and Miyano, M. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745.
53. Ruan, K.-H., So, S.-P., Wu, J., Li, D., Huang, A. and Kung, J. (2001) Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry 40, 275-280.
54. Wu, J., So, S.-P. and Ruan, K.-H. (2003) Solution structure of the third extracellular loop of human thromboxane A2 receptor. Arch. Biochem. Biophys. 414, 287-293.
55. Dorn, G.W.2nd (1990) Cyclic oxidation-reduction reactions regulate thromboxane A2/prostaglandin H2 receptor number and affinity in human platelet membranes. J. Biol. Chem. 265, 4240-4246.
56. D’Angelo, D.D., Eubank, J.J., Davis, M.G. and Dorn, G.W.2nd. (1996) Mutagenic analysis of platelet thromboxane receptor cysteines. J. Biol. Chem. 271, 6233-6240.
57. Mayeux, P.R., Morinelli, T.A., Williams, T.C., Hazard, E.S., Mais, D.E., Oatis, J.E., Baron, D.A. and Halushka, P.V. (1991) Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human platelets. J. Biol. Chem. 266, 13752-13758.
58. Dorn, G.W.2nd, Davis, M.G. and D’Angelo, D.D. (1997) Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J. Biol. Chem. 272, 12399-12405.
59. Dogne, J.M., de Leval, X., Delarge, J., David, J.L. and Masereel, B. (2000) New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem. 7, 609-628.
60. Von Baeyer, H., Hopfenmuller, W., Riedel, E. and Affeld, K. (2003) Atherosclerosis:current concepts of pathophysiology and pharmacological intervention based on trial outcomes. Clin. Nephrol. 60 (Suppl 1), 31-48.
61. McAdam, B.F., Catella-Lawson, F., Mardini, I.A., Kapoor, S., Lawson, J.A. and FitzGerald, G.A. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96, 272-277.
62. Reis, E.D., Roque, M., Dansky, H., Fallon, J.T., Badimon, J.J., Cordon-Cardo, C., Shiff, S.J. and Fisher, E.A. (2000) Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 97, 12764-12769.
63. Pratico, D., Tillmann, C., Zhi-Bing, Z., Hongwei, L. and FitzGerald, G.A. (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. USA 98, 3358-3363.
64. Kvasnicka, T., (2003) NO (nitric oxide) and its significance in regulation of vascular homeostasis. Vnitr. Lek. 49, 291-296.
65. Arbab, F., Goldsby, J., Matijevic-Aleksic, N., Huang, G., Ruan, K.H. and Huang, J.C. (2002) Prostacyclin is an autocrine regulator in the contraction of oviductal smooth muscle. Hum. Reprod. 17, 3053-3059.
66. Huang, J.C., Arbab, F., Tumbusch, K.J., Goldsby, J.S., Matijevic-Aleksic, N. and Wu, K.K. (2002) Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI. J. Clin. Endocrinol. Metab. 87, 4361-4368.
67. Debey, S., Meyer-Kirchrath, J. and Schror, K. (2003) Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER. Biochem. Pharmacol. 65, 979-988.
68. Ruan, K.-H., So, S.-P., Zheng, W., Wu, J., Li, D. and Kung, J. (2002) Solution structure and topology of the N-terminal membrane anchor domain of a microsomal cytochrome P450: prostaglandin I2 synthase. Biochem. J. 368, 1-7.
69. Lin, Y.Z., Deng, H. and Ruan, K.-H. (2000) Topology of catalytic portion of prostaglandin I(2) synthase: identification by molecular modeling-guided site-specific antibodies. Arch. Biochem. Biophys. 379, 188-197.
70. Deng, H., Huang, A., So, S.P., Lin, Y.Z. and Ruan, K.-H. (2002) Substrate access channel topology in membrane-bound prostacyclin synthase. Biochem. J. 362, 545-551.
71. Boie, Y., Rushmore, T.H., Darmon-Goodwin, A., Grygorczyk, R., Slipetz, D.M., Metters, K.M. and Abramovitz, M.J. (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 269, 12173-12178.
72. Nakagawa, O., Tanaka, I., Usui, T., Harada, M., Sasaki, Y., Itoh, H., Yoshimasa, T., Namba, T., Narumiya, S. and Nakao, K. (1994) Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90, 1643-1647.
73. Kaliman, J., Sinzinger, H., Staudacher, M. and Mannheimer, E. (1985) Defects in the prostaglandin system. II. Familial platelet-prostacyclin receptor defect (Wien-Hietzing defect)--pathogenetic significance for (early) development of atherosclerosis? Wien Klin Wochenschr 97, 323-326.
74. Watanabe, Y., Matsumura, K., Takechi, H., Kato, K., Morii, H., Bjorkman, M., Langstrom, B., Noyori, R., Suzuki, M. and Watanabe, Y. (1999) A novel subtype of prostacyclin receptor in the central nervous system. J. Neurochem. 72, 2583-2592.
75. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
76. Zhang, J., Fu, M., Zhu, X., Xiao, Y., Mou, Y., Zheng, H., Akinbami, M.A., Wang, Q. and Chen, Y.E. (2002) Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J. Biol. Chem. 277, 11505-11512.
77. Plutzky, J. (2003) Medicine. PPARs as therapeutic targets: reverse cardiology? Science 302, 406-407.
78. Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. and Walsh, K. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14, 561-566.
79. Gonzalez, M.A., and Selwyn, A.P. (2003) Endothelial function, inflammation, and prognosis in cardiovascular disease. Am. J. Med. 115 Suppl 8A, 99S-106S.
80. Murakami, M., Nakatani, Y., Tanioka, T. and Kudo, I. (2002) Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 68-69, 383-399.
81. Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M. and Kudo, I. (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275, 32775-32782.
82. Murakami, M., Nakashima, K., Kamei, D., Masuda, S., Ishikawa, Y., Ishii, T., Ohmiya, Y., Watanabe, K. and Kudo, I. (2003) Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 278, 37937-37947.
83. Cipollone, F., Prontera, C., Pini, B., Marini, M., Fazia, M., De Cesare, D., Iezzi, A., Ucchino, S., Boccoli, G., Saba, V., Chiarelli, F., Cuccurullo, F., Mezzetti, A. (2001) Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)- dependent plaque instability. Circulation 104, 921-927.